Mechanism for anti-tumor effect of OK-432 and development of novel treatment strategy in oral cancer
Mechanism for anti-tumor effect of OK-432 and development of novel treatment strategy in oral cancer
批准号:
16592005
负责人:
OKAMOTO Masato
金额:
$2.3万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2005
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We have succeeded in isolating an active component of OK-432, a lipoteichoic acid-related molecule OK-PSA, and have shown that the OK-PSA augments anti-cancer immunity via Toll-like receptor (TLR) 4. In the current study, we demonstrated that IL-12-inducing ability of OK-432 was inhibited by cytochalasin B, a phagocytosis inhibitor, in human dendritic cells (DCs) and in mouse peritoneal macrophages (PMs), that OK-432 was captured and dissolved by DCs and PMs, that these is an OK-PSA in the supernatant derived from OK-432-treated DCs, that the supernatant increased nuclear factor-κB activity in TLR4-expressing cells and the activity was neutralized by TS-2 antibody recognizing OK-PSA, and that OK-432 administration resulted in inhibiting tumor growth in tumor-bearing mice and OK-PSA was detected in the sera from the mice. It was indicated that capture of OK-432 by phagocytes and TLR4 signaling play significant roles in anti-cancer immune effect of OK-432. Next, we investigated the strategy for treating oral cancer patients who do not express TLR4. In syngeneic tumor-bearing TLR4-/- mice, DC+OK-432 therapy did not elicit antitumor effect, however, this therapy was effective when TLR4 gene was transfected into TLR4-/- mice-derived DCs. It was strongly suggested that the therapy using TLR4 gene-transfected DCs+OK-432 may be effectve for the treatment of cancer patients who did not express TLR4 and was supposed non-responder to OK-432-based immunotherapy.
期刊论文(150)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Expression of Toll-like receptor 2, 4 and 9 in human head and neck cancer cell lines and their responsiveness against each ligand.
Toll 样受体 2、4 和 9 在人头颈癌细胞系中的表达及其对每种配体的反应性。
DOI:
--
发表时间:
2005
期刊:
J Jpn Stomatol Soc 54(3)
影响因子:
--
作者:
[笠井久美子, 府川俊彦, 山崎安晴, Masato Okamoto, Takaaki Sagawa, 山崎安晴, Tomiyuki Tano, Tomoyuki Tano]
通讯作者:
Tomoyuki Tano
担癌マウスにおけるTS-1およびOK-432併用樹状細胞腫瘍内投与療法の抗腫瘍効果
瘤内树突状细胞联合TS-1和OK-432治疗荷瘤小鼠的抗肿瘤作用
DOI:
--
发表时间:
2004
期刊:
癌と化学療法 31・11
影响因子:
--
作者:
[Junko Kawashima, Shinichi Takahashi et al., 岡本正人]
通讯作者:
岡本正人
Anti-tumor effect of intratumoral administration of dendritic cells in combination with TS-1 and OK-432.
树突状细胞与 TS-1 和 OK-432 联合瘤内给药的抗肿瘤作用。
DOI:
--
发表时间:
2004
期刊:
Jpn J Cancer Chemother 31(11)
影响因子:
--
作者:
[S.OKA, C.Richard CHAPMAN, B.KIM, I.NAKAJIMA, O.SHIMIZU, Y.OI, Kazuhiro Hasegawa, Sharif Uddin Ahmed, 茂木勝美, Hiroaki Omata, Masato Okamoto]
通讯作者:
Masato Okamoto
OK-432の免疫活性化機構の解析:貪食、活性成分の遊出とTLR4シグナルの活性化
OK-432免疫激活机制解析:吞噬、活性成分释放、TLR4信号激活
DOI:
--
发表时间:
2004
期刊:
癌と化学療法 31・11
影响因子:
--
作者:
[T.Wakira, M.Mogi, K.Kurita, M.Kuzushima, A.Togari, Masato Okamoto, 小俣裕昭 他4名, 押川哲也, Hiroyuki Nakagawa, Wakita et al., 小俣裕昭 他4名, Koji Harada, Sharif Uddin Ahmed, 田野智之]
通讯作者:
田野智之
Streptococcal preparation, OK-432-based immunotherapy for head and neccancer : Possible stimulation of dendritic cells via Toll-Like Receptor4
链球菌制剂、基于 OK-432 的头癌和宫颈癌免疫疗法:可能通过 Toll 样受体 4 刺激树突状细胞
DOI:
--
发表时间:
2005
期刊:
影响因子:
--
作者:
[T.Wakira, M.Mogi, K.Kurita, M.Kuzushima, A.Togari, Masato Okamoto, 小俣裕昭 他4名, 押川哲也, Hiroyuki Nakagawa, Wakita et al., 小俣裕昭 他4名, Koji Harada, Sharif Uddin Ahmed, 田野智之, Koji Harada, Hiroaki Omata, 両馬良樹, Hiroaki Omata, Koji Harada, Hiroaki Omata, Masato Okamoto]
通讯作者:
Masato Okamoto
共 52 条
Development of small low pressure wind tunnel and study on aerodynamic characteristics of insect sized wing at very low Reynolds number
-
批准号:25630395
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.08万
-
财政年份:2013
-
负责人:OKAMOTO Masato
-
依托单位:
Establishment of dendritic cell-based vaccine in combination with chemotherapy for oral cancer patients
-
批准号:22592247
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.83万
-
财政年份:2010
-
负责人:OKAMOTO Masato
-
依托单位:
Comprehensive analysis of Toll-like receptor-related genes in oral cancer patients and development of individual cancer immunotherapy
-
批准号:18390543
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.02万
-
财政年份:2006
-
负责人:OKAMOTO Masato
-
依托单位:
Development of a local dendritic cell-therapy by using an active component of OK-432 ; Involvement of Toll-like receptor 4
-
批准号:14571898
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.11万
-
财政年份:2002
-
负责人:OKAMOTO Masato
-
依托单位:
Cytokine-inducing and anti-cancer effects of 5-FU and CDDP, chemotherapeutic agents, in oral cancer patients
-
批准号:12671942
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2000
-
负责人:OKAMOTO Masato
-
依托单位:
THE RILE OF TUMOR-DERIVED IL-6 IN MANDIBULAR BONE INVASION OF ORAL CANCER
-
批准号:10671886
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:OKAMOTO Masato
-
依托单位:
国内基金
海外基金
登录
查看更多内容
OSMI-4靶向O-糖基化调控PD-L1联合裂解OK-432协同治疗不完全消融后残存肝癌的机制研究
-
批准号:JCZRLH202600261
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
OK-432联合PD-1单抗治疗肝癌射频消融后残存和远处转移瘤的机制及疗效研究
-
批准号:82072041
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:阚雪锋
-
依托单位:
OK-432和西地那非治疗儿童淋巴管畸形机制的探讨
-
批准号:81300238
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:侯昉
-
依托单位:
OK-432肿瘤疫苗抗肿瘤作用的信号传导机制
-
批准号:81141091
-
项目类别:专项基金项目
-
资助金额:10.0万元
-
批准年份:2011
-
负责人:李宪起
-
依托单位: